Table 1: Patient and disease characteristics.
|
Feature |
No. (%) |
|
All patients |
56 (100) |
|
Initial Stage |
|
|
Early |
18 (32) |
|
Metastatic |
38 (68) |
|
Histology |
|
|
Invasive ductal |
53 (95) |
|
Lobular |
3 (5) |
|
Grade |
|
|
Low |
2 (4) |
|
Intermediate |
17 (30) |
|
High |
26 (46) |
|
Unknown |
11 (20) |
|
ER |
|
|
Positive |
38 (68) |
|
Negative |
18 (32) |
|
PR |
|
|
Positive |
29 (52) |
|
Negative |
25 (44) |
|
Unknown |
2 (4) |
|
HER-2 |
|
|
Positive |
4 (7) |
|
Negative |
52 (93) |
|
Ki67 |
|
|
Positive (≥ 10) |
36 (64) |
|
Negative |
6 (11) |
|
Unknown |
14 (25) |
|
Adjuvant chemotherapy |
|
|
Yes |
32(57) |
|
No |
4 (7) |
|
Not applicable |
18 (32) |
|
Unknown |
2 (4) |
|
Adjuvant endocrine therapy |
|
|
Yes |
20 (36) |
|
No |
2 (7) |
|
Not applicable |
30 (54) |
|
Unknown |
4 (7) |
|
GP was requested for none-recurrent or non-metastatic disease |
5 (8)
|
ER: Estrogen Receptor; GP: Genomic Profiling; PR: Progesterone Receptor